Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...

Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.

In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

Sarepta is currently testing SRP-9001 in the placebo-controlled EMBARK study, which aims to enrol 120 boys with DMD aged four to seven and is due to read out in the latter half of 2023.

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a ...